Nalaganje...
Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
Although there have been significant insights into the biology of diffuse large B-cell lymphoma (DLBCL) over recent years, progress in our therapeutic approach has been disappointing over the same timeframe. This is not for want of trying. In 2017, R-CHOP (rituximab plus cyclophosphamide, doxorubici...
Shranjeno v:
| izdano v: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142538/ https://ncbi.nlm.nih.gov/pubmed/29222268 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|